Screener
Apogee Therapeutics, Inc. APGE Business Segments — Depreciation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| External-discovery related costs and other (2) | 8,433 | 5,437 |
| General and administrative personnel-related (excluding equity-based compensation) | 7,985 | 5,707 |
| General and administrative operations(3) | 5,009 | 5,105 |
| Equity-based compensation | 17,155 | 11,126 |
| Depreciation expense | 408 | 207 |
| Interest income, net | (8,740) | (7,840) |
| Provision for income taxes | 79 | 83 |
| Consolidated net loss | $74,111 | $55,339 |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s business segments — depreciation?
- Apogee Therapeutics, Inc. (APGE) reported business segments — depreciation of $408K in Q1 2026.
- How has Apogee Therapeutics, Inc.'s business segments — depreciation changed year-over-year?
- Apogee Therapeutics, Inc.'s business segments — depreciation increased by 97.1% year-over-year, from $207K to $408K.
- What does business segments — depreciation mean?
- This metric represents the systematic allocation of the cost of tangible assets over their useful lives within the operating segment. It reflects the consumption of capital equipment and laboratory infrastructure used to support business operations. Higher depreciation indicates a larger investment in physical assets and equipment.
Ask your AI about Apogee Therapeutics, Inc.'s business segments — depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude